Morgan Lewis

Life Sciences Transactions Publications of Interest

For More Information

Read the brochure

Emerging Business Tools

visit the Entrepreneur Resource Headquarters

Related Publications

06/19/08 From Europe and Japan to the U.S.: Build or Buy?, presented at the 2008 BIO International Convention, San Diego, CA
05/24/05 Pharmaceutical Industry Mergers: Anticipating Antitrust Issues and Surviving the Investigation, presented at the American Conference Institute In-House Counsel Forum on Pharmaceutical Antitrust, Washington, D.C.
View all publications

Related News

09/16/14 Morgan Lewis Tops BioPharm Insight Second-Quarter League Tables
Morgan Lewis is pleased to announce that its Life Sciences and Healthcare practice has again placed among the top firms in BioPharm Insight ’s quarterly league tables.
04/11/13 Morgan Lewis Advises MEI Pharma on $15.2 Million Registered Offering of Common Stock
Morgan Lewis served as legal adviser to MEI Pharma, Inc. on registered offering of common stock.
10/29/10 Morgan Lewis Advises Safeguard Scientifics on $587 Million Sale of Clarient to GE Healthcare
In a transaction valued at $587 million, Clarient, Inc. has agreed to be acquired by GE Healthcare.
View all news

Honors

BioPharm Insight 2013 Q3

  • Ranked 1st – Legal Advisors to Biotech and Pharma Licensing Agreements: Asia-Pacific – Based on Value
  • Ranked 2nd – Legal Advisors to Biotech and Pharma Licensing Agreements: Asia-Pacific – Based on Volume
  • Ranked 3rd – Legal Advisors to Biotech and Pharma Licensing Agreements: Europe – Based on Value
  • Ranked 8th – Legal Advisors to Biotech and Pharma Licensing Agreements: Europe – Based on Volume
  • Ranked 7th – Global League Table of Legal Advisors to Biotech and Pharma Licensing Agreements – Based on Value
  • Ranked 9th – Global League Table of Legal Advisors to Biotech and Pharma Licensing Agreements – Based on Volume
  • Ranked 10th – Legal Advisors to Biotech and Pharma Licensing Agreements: North America – Based on Value
  • Ranked 10th – Legal Advisors to Biotech and Pharma Licensing Agreements: North America – Based on Volume
14 Publications Found
page 1 of 1
10/28/10 Preparing for a Biotechnology M&A – Corporate and Regulatory Insight to Keep Ahead of the Competition

Presentation | Speech
Stephen Mahinka, Richard Aldridge

06/19/08 From Europe and Japan to the U.S.: Build or Buy?, presented at the 2008 BIO International Convention, San Diego, CA

Presentation | Speech
Randall Sunberg

05/24/05 Pharmaceutical Industry Mergers: Anticipating Antitrust Issues and Surviving the Investigation, presented at the American Conference Institute In-House Counsel Forum on Pharmaceutical Antitrust, Washington, D.C.

Presentation | Speech
Stephen Mahinka

10/29/04 Making 50-50 Collaborations Work Effectively, presented to JP Morgan Chase, Newport Conference Center

Presentation | Speech
Randall Sunberg

10/17/04 Biotech and Pharma M&A and Collaborations: Protecting the Deal and Preserving Your Upside, LES Annual Meeting, Boston

Presentation | Speech
Randall Sunberg

10/13/04 Outline of Issues for a Biotech Company to Consider in Preparing for an IPO

Presentation | Speech
Steven Cohen

10/05/04 Biotech and Pharma M&A and Collaborations: Protecting the Deal and Preserving Your Upside, presented at Biotech 2004, Philadelphia

Presentation | Speech
Randall Sunberg

07/24/04 Strategic Alliances and Business Development, presented at the BioForum 2004, Shanghai

Presentation | Speech
Randall Sunberg

02/13/04 Protecting Your Downside While Maximizing Your Upside: Protective Provisions in Biotech Deals, presented at the LES Winter Meeting, San Francisco

Presentation | Speech
Randall Sunberg

09/09/03 Pharma and Biotech Collaborations, PA Biotech, 3 Rivers Venture Fair

Presentation | Speech
Randall Sunberg

06/24/03 Getting from Biotech to BIG Biotech, BIO 2003, Washington, DC

Presentation | Speech
Randall Sunberg

04/30/03 Closing Plenary Session: Facilitating Global Reach in the Life Sciences Industry, BIOTechnica America, Monterey, CA

Presentation | Speech
Randall Sunberg

January/February 2003 Morgan Lewis on Life Sciences
January/February 2003

Newsletter | Morgan Lewis on Life Sciences
Life Sciences

In this Issue: A Shift in the Hatch-Waxman Balance: FDA's Proposed Rule: The Hatch-Waxman Act, which created today’s generic drug system, was premised on balancing two divergent interests — facilitating the approval... more

July 2002 Morgan Lewis on Life Sciences
July 2002

Newsletter | Morgan Lewis on Life Sciences
Life Sciences

In this Issue: Welcome and Introduction BuSpar® and Tiazac® Antitrust Cases Leave Unanswered Questions: Over the last few years, an increasing number of antitrust cases have challenged various action... more

page 1 of 1